Genenta poised to become first Italian biotech to list on NASDAQ

Italy is on the cusp of seeing its first biotech list on NASDAQ now that Genenta has filed to raise up to $34.5 million on the U.S. market. 

The proposed deal would mark the second Italian biotech to go public in the past decade, according to BioCentury’s BCIQ database. The most recent was Cassiopea S.p.A. (SIX:SKIN), a dermatology spinout from Cosmo Pharmaceuticals N.V. (SIX:COPN), completed its IPO in 2015...